Management of Immune-Related Adverse Events Affecting Outcome in Patients Treated With Checkpoint Inhibitors
JAMA Oncol
.
2020 Aug 1;6(8):1300-1301.
doi: 10.1001/jamaoncol.2020.1932.
Authors
Karijn P M Suijkerbuijk
1
,
Ellen Kapiteijn
2
,
Rik J Verheijden
1
Affiliations
1
Department of Medical Oncology, University Medical Center Utrecht Cancer Center, Utrecht, the Netherlands.
2
Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
PMID:
32556062
DOI:
10.1001/jamaoncol.2020.1932
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized / adverse effects
Humans
Melanoma* / drug therapy
Skin Neoplasms*
Substances
Antibodies, Monoclonal, Humanized
pembrolizumab